The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms

Karin C.Lødrup Carlsen, Steve Stick, Wolfgang Kamin, Ieva Cirule, Sara Hughes, Claire Wixon

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


We aimed to evaluate the efficacy and safety of fluticasone propionate (FP) in children aged 12-47 months with recurrent/persistent asthma symptoms. One hundred and sixty children (12-47 months) were randomised into this multicentre, double-blind, placebo-controlled, parallel-group study, and treated with either FP (100 μg bd) or placebo (2 puffs bd), both administered by metered-dose-inhaler and Babyhaler™ for 12 weeks. The primary endpoint was percentage of symptom-free 24 h periods. Over weeks 1-12, FP-treated patients had significantly more percentage symptom-free 24-h periods compared with placebo (odds ratio 0.53; 95% CI 0.29-0.95; P = 0.035). Relative to baseline, where all patients were symptomatic for at least 21/28 days of the run-in, the improvement equated to one additional symptom-free 24 h period per week. FP patients also had a significantly higher percentage of 24 h periods with no wheeze or cough, the odds ratio for treatment difference corresponding to two additional wheeze-free and one additional cough-free periods per week. FP was well-tolerated, with similar reported adverse events in both groups. Urinary cortisol-creatinine ratio was slightly decreased among FP patients after 12 weeks, but with no clinical correlates. FP is effective for the treatment of chronic persistent asthma symptoms in very young children.

Original languageEnglish
Pages (from-to)1393-1402
Number of pages10
JournalRespiratory Medicine
Issue number11
Publication statusPublished - Nov 2005
Externally publishedYes


Dive into the research topics of 'The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms'. Together they form a unique fingerprint.

Cite this